GHDX Key Statistics, Chart & Performance
The current stock price of GHDX is 63.44 null. In the past month the price decreased by -6.57%. In the past year, price decreased by -22.32%.
GHDX Technical Analysis
GHDX Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to GHDX. While GHDX has a great health rating, its profitability is only average at the moment.
GHDX Financial Highlights
Over the last trailing twelve months GHDX reported a non-GAAP Earnings per Share(EPS) of 1.4300000000000002. The EPS increased by 186% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 12.81% | ||
| ROA | 12.29% | ||
| ROE | 16.2% | ||
| Debt/Equity | 0.15 |
GHDX Forecast & Estimates
GHDX Ownership
About GHDX
Company Profile
Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. It launched its first test, Oncotype DX, which has been shown to predict the likelihood of breast cancer recurrence and chemotherapy benefit in early stage breast cancer patients. The Oncotype DX assay represents the first diagnostic gene expression test on the market that provides consistent results across multiple independent trials having breast cancer patients, including a large validation study of The New England Journal of Medicine.
Company Info
GENOMIC HEALTH INC
301 PENOBSCOT DRIVE
REDWOOD CITY CA 94063
CEO: Kimberly J. Popovits
Phone: 650-556-9300
GENOMIC HEALTH INC / GHDX FAQ
Can you describe the business of GENOMIC HEALTH INC?
Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. It launched its first test, Oncotype DX, which has been shown to predict the likelihood of breast cancer recurrence and chemotherapy benefit in early stage breast cancer patients. The Oncotype DX assay represents the first diagnostic gene expression test on the market that provides consistent results across multiple independent trials having breast cancer patients, including a large validation study of The New England Journal of Medicine.
What is the stock price of GENOMIC HEALTH INC today?
The current stock price of GHDX is 63.44 null. The price decreased by -0.69% in the last trading session.
Does GENOMIC HEALTH INC pay dividends?
GHDX does not pay a dividend.
What is the ChartMill rating of GENOMIC HEALTH INC stock?
GHDX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the market capitalization of GHDX stock?
GENOMIC HEALTH INC (GHDX) has a market capitalization of 2.38B null. This makes GHDX a Mid Cap stock.